Drug
PF-05231023 clinical trials
Also written PF-05231023.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses PF-05231023 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 DiabetesCompletedPhase 1PfizerNCT01285518Written as PF-05231023
- Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes MellitusCompletedPhase 1PfizerNCT01673178Written as 25 mg PF-05231023
- Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 DiabetesCompletedPhase 1PfizerNCT01396187Written as PF-05231023
- Multiple Dose Study Of PF-05231023 In Obese Adult SubjectsTerminatedPhase 1PfizerNCT01923389Written as 100 mg PF-05231023